Today's issue of the Journal of the American Medical Association includes an important new article on improved ovarian cancer survival for BRCA mutation carriers co-authored by Dr. Ora Gordon, co-author of Positive Results. A link to the JAMA article can be found here.
A summary of the study's conclusion is that for patient's diagnosed with epithelial ovarian cancer, both BRCA1 mutations and BRCA2 mutations confer improved 5-year survival, independent of cancer stage at diagnosis. Confirming the conclusion of prior studies, the new analysis found that BRCA2 carriers have the best disease prognosis.
This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. Inquiries regarding rights should be directed to the authors.